S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
S&P 500   3,901.82
DOW   31,535.51
QQQ   323.59
pixel
pixel
Log in
LON:NIPT

Premaitha Health PLC (NIPT.L) Competitors

GBX 9.10
+0.20 (+2.25 %)
(As of 11/6/2018)
Add
Compare
Today's Range
9.10
Now: GBX 9.10
9.10
50-Day Range
9.10
MA: GBX 9.10
9.10
52-Week Range
3.78
Now: GBX 9.10
14.80
Volume1.57 million shs
Average Volume1.35 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Premaitha Health PLC (NIPT.L) (LON:NIPT) Vs. AZN, GSK, SN, HIK, CTEC, and DPH

Should you be buying NIPT stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Premaitha Health PLC (NIPT.L), including AstraZeneca (AZN), GlaxoSmithKline (GSK), Smith & Nephew (SN), Hikma Pharmaceuticals (HIK), Convatec Group (CTEC), and Dechra Pharmaceuticals PLC (DPH.L) (DPH).

AstraZeneca (LON:AZN) and Premaitha Health PLC (NIPT.L) (LON:NIPT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation.

Profitability

This table compares AstraZeneca and Premaitha Health PLC (NIPT.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AstraZenecaN/AN/AN/A
Premaitha Health PLC (NIPT.L)N/AN/AN/A

Valuation & Earnings

This table compares AstraZeneca and Premaitha Health PLC (NIPT.L)'s gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AstraZeneca£26.62 billion3.42N/AGBX 243.6028.49
Premaitha Health PLC (NIPT.L)N/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and target prices for AstraZeneca and Premaitha Health PLC (NIPT.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
AstraZeneca511402.45
Premaitha Health PLC (NIPT.L)0000N/A

AstraZeneca currently has a consensus target price of GBX 8,639.41, suggesting a potential upside of 24.27%. Given AstraZeneca's higher probable upside, equities analysts clearly believe AstraZeneca is more favorable than Premaitha Health PLC (NIPT.L).

Summary

AstraZeneca beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) (LON:NIPT) and GlaxoSmithKline (LON:GSK) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, risk, valuation, institutional ownership, analyst recommendations and earnings.

Valuation & Earnings

This table compares Premaitha Health PLC (NIPT.L) and GlaxoSmithKline's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Premaitha Health PLC (NIPT.L)N/AN/AN/AN/AN/A
GlaxoSmithKline£34.10 billion1.78N/AGBX 114.1010.56

Profitability

This table compares Premaitha Health PLC (NIPT.L) and GlaxoSmithKline's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Premaitha Health PLC (NIPT.L)N/AN/AN/A
GlaxoSmithKlineN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Premaitha Health PLC (NIPT.L) and GlaxoSmithKline, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Premaitha Health PLC (NIPT.L)0000N/A
GlaxoSmithKline38502.13

GlaxoSmithKline has a consensus target price of GBX 1,572.31, indicating a potential upside of 30.23%. Given GlaxoSmithKline's higher possible upside, analysts plainly believe GlaxoSmithKline is more favorable than Premaitha Health PLC (NIPT.L).

Summary

GlaxoSmithKline beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) (LON:NIPT) and Smith & Nephew (LON:SN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, analyst recommendations, profitability, dividends and earnings.

Profitability

This table compares Premaitha Health PLC (NIPT.L) and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Premaitha Health PLC (NIPT.L)N/AN/AN/A
Smith & NephewN/AN/AN/A

Analyst Recommendations

This is a summary of current ratings and recommmendations for Premaitha Health PLC (NIPT.L) and Smith & Nephew, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Premaitha Health PLC (NIPT.L)0000N/A
Smith & Nephew15402.30

Smith & Nephew has a consensus target price of GBX 1,769.71, suggesting a potential upside of 27.32%. Given Smith & Nephew's higher probable upside, analysts plainly believe Smith & Nephew is more favorable than Premaitha Health PLC (NIPT.L).

Valuation and Earnings

This table compares Premaitha Health PLC (NIPT.L) and Smith & Nephew's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Premaitha Health PLC (NIPT.L)N/AN/AN/AN/AN/A
Smith & Nephew£4.56 billion2.67N/AGBX 51.2027.15

Summary

Smith & Nephew beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Premaitha Health PLC (NIPT.L) (LON:NIPT) and Hikma Pharmaceuticals (LON:HIK) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares Premaitha Health PLC (NIPT.L) and Hikma Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Premaitha Health PLC (NIPT.L)N/AN/AN/A
Hikma PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares Premaitha Health PLC (NIPT.L) and Hikma Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Premaitha Health PLC (NIPT.L)N/AN/AN/AN/AN/A
Hikma Pharmaceuticals£2.34 billion2.21N/AGBX 181.1012.39

Analyst Ratings

This is a summary of current ratings and target prices for Premaitha Health PLC (NIPT.L) and Hikma Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Premaitha Health PLC (NIPT.L)0000N/A
Hikma Pharmaceuticals02602.75

Hikma Pharmaceuticals has a consensus target price of GBX 2,478.57, suggesting a potential upside of 10.35%. Given Hikma Pharmaceuticals' higher possible upside, analysts plainly believe Hikma Pharmaceuticals is more favorable than Premaitha Health PLC (NIPT.L).

Summary

Hikma Pharmaceuticals beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Convatec Group (LON:CTEC) and Premaitha Health PLC (NIPT.L) (LON:NIPT) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability.

Earnings and Valuation

This table compares Convatec Group and Premaitha Health PLC (NIPT.L)'s top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Convatec Group£1.85 billion2.05N/AGBX 1.20157.08
Premaitha Health PLC (NIPT.L)N/AN/AN/AN/AN/A

Profitability

This table compares Convatec Group and Premaitha Health PLC (NIPT.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Convatec GroupN/AN/AN/A
Premaitha Health PLC (NIPT.L)N/AN/AN/A

Analyst Ratings

This is a summary of current ratings and price targets for Convatec Group and Premaitha Health PLC (NIPT.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Convatec Group36201.91
Premaitha Health PLC (NIPT.L)0000N/A

Convatec Group presently has a consensus target price of GBX 206, indicating a potential upside of 9.28%. Given Convatec Group's higher probable upside, analysts clearly believe Convatec Group is more favorable than Premaitha Health PLC (NIPT.L).

Summary

Convatec Group beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.

Dechra Pharmaceuticals PLC (DPH.L) (LON:DPH) and Premaitha Health PLC (NIPT.L) (LON:NIPT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.

Valuation and Earnings

This table compares Dechra Pharmaceuticals PLC (DPH.L) and Premaitha Health PLC (NIPT.L)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dechra Pharmaceuticals PLC (DPH.L)£566.40 million6.50N/AGBX 41.4082.27
Premaitha Health PLC (NIPT.L)N/AN/AN/AN/AN/A

Profitability

This table compares Dechra Pharmaceuticals PLC (DPH.L) and Premaitha Health PLC (NIPT.L)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dechra Pharmaceuticals PLC (DPH.L)N/AN/AN/A
Premaitha Health PLC (NIPT.L)N/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Dechra Pharmaceuticals PLC (DPH.L) and Premaitha Health PLC (NIPT.L), as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dechra Pharmaceuticals PLC (DPH.L)02202.50
Premaitha Health PLC (NIPT.L)0000N/A

Dechra Pharmaceuticals PLC (DPH.L) presently has a consensus price target of GBX 3,077.50, indicating a potential downside of 9.64%. Given Dechra Pharmaceuticals PLC (DPH.L)'s higher possible upside, research analysts clearly believe Dechra Pharmaceuticals PLC (DPH.L) is more favorable than Premaitha Health PLC (NIPT.L).

Summary

Dechra Pharmaceuticals PLC (DPH.L) beats Premaitha Health PLC (NIPT.L) on 3 of the 3 factors compared between the two stocks.


Premaitha Health PLC (NIPT.L) Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
AstraZeneca logo
AZN
AstraZeneca
2.0$6,939.00+0.6%£91.63 billion£26.62 billion28.49Analyst Report
GlaxoSmithKline logo
GSK
GlaxoSmithKline
2.3$1,204.40+0.3%£60.40 billion£34.10 billion10.56Analyst Report
Smith & Nephew logo
SN
Smith & Nephew
1.7$1,390.00+0.3%£12.19 billion£4.56 billion27.15News Coverage
Hikma Pharmaceuticals logo
HIK
Hikma Pharmaceuticals
1.6$2,243.76+0.2%£5.18 billion£2.34 billion12.39Dividend Increase
Convatec Group logo
CTEC
Convatec Group
1.0$188.50+0.2%£3.78 billion£1.85 billion157.08Upcoming Earnings
Dechra Pharmaceuticals PLC (DPH.L) logo
DPH
Dechra Pharmaceuticals PLC (DPH.L)
0.9$3,406.00+1.1%£3.72 billion£566.40 million82.27Gap Up
Abcam plc (ABC.L) logo
ABC
Abcam plc (ABC.L)
0.7$1,597.00+0.3%£3.63 billion£260 million266.17Upcoming Earnings
Genus plc (GNS.L) logo
GNS
Genus plc (GNS.L)
1.0$5,205.00+0.0%£3.40 billion£551.40 million84.09Dividend Cut
Gap Down
BTG logo
BTG
BTG
0.8$840.00+0.1%£3.26 billion£914.10 million29.47
Mediclinic International plc (MDC.L) logo
MDC
Mediclinic International plc (MDC.L)
0.9$291.60+0.4%£2.14 billion£2.98 billion-5.19
UDG Healthcare logo
UDG
UDG Healthcare
1.7$779.86+0.5%£1.95 billion£1.28 billion21.19
PureTech Health logo
PRTC
PureTech Health
1.5$416.50+0.5%£1.18 billion£12.26 million2.63Gap Down
Clinigen Group plc (CLIN.L) logo
CLIN
Clinigen Group plc (CLIN.L)
1.6$719.00+0.4%£952.49 million£518.70 million74.12Dividend Cut
Indivior PLC (INDV.L) logo
INDV
Indivior PLC (INDV.L)
1.4$129.10+0.1%£948.40 million£647 million-6.39
Oxford Biomedica plc (OXB.L) logo
OXB
Oxford Biomedica plc (OXB.L)
0.8$1,028.00+0.6%£841.85 million£65.94 million-62.68
MaxCyte logo
MXCT
MaxCyte
0.5$984.90+0.5%£766.48 million£24.14 million-61.94
Vectura Group plc (VEC.L) logo
VEC
Vectura Group plc (VEC.L)
1.2$112.20+0.2%£669.86 million£176.30 million-93.50Gap Down
RENX
Renalytix AI plc (RENX.L)
0.6$880.00+2.8%£615.86 million£105,000.00-36.36Gap Down
Ergomed logo
ERGO
Ergomed
0.6$1,212.00+3.1%£609 million£73.46 million96.96Gap Up
UPR
Uniphar
0.2$212.50+0.0%£600.63 million£1.74 billion2,168.37Dividend Announcement
Spire Healthcare Group logo
SPI
Spire Healthcare Group
1.1$150.93+1.5%£596.01 million£891.10 million-2.60Upcoming Earnings
CareTech logo
CTH
CareTech
1.6$519.79+0.3%£586.80 million£429.97 million23.63
Consort Medical plc (CSRT.L) logo
CSRT
Consort Medical plc (CSRT.L)
0.9$1,010.00+0.5%£504.60 million£298.60 million127.85News Coverage
Advanced Medical Solutions Group logo
AMS
Advanced Medical Solutions Group
0.6$234.90+0.6%£503.13 million£92.94 million37.29Upcoming Earnings
News Coverage
Gap Down
NCYT
Novacyt S.A. (NCYT.L)
0.4$718.75+1.8%£498.62 millionN/A-27.43
Silence Therapeutics plc (SLN.L) logo
SLN
Silence Therapeutics plc (SLN.L)
0.7$598.00+0.7%£494.86 million£1.39 million-21.28
Avacta Group Plc (AVCT.L) logo
AVCT
Avacta Group Plc (AVCT.L)
0.5$197.93+1.5%£492.67 million£4.64 million-25.38
Alliance Pharma logo
APH
Alliance Pharma
0.7$86.00+0.7%£455.34 million£131.34 million40.95
Amryt Pharma logo
AMYT
Amryt Pharma
0.5$213.25+0.1%£389.79 million£180.38 million-3.72Upcoming Earnings
Benchmark logo
BMK
Benchmark
0.9$57.80+0.5%£388.11 million£109.90 million-13.44
Beximco Pharmaceuticals logo
BXP
Beximco Pharmaceuticals
0.5$86.00+0.0%£383.66 millionN/A0.00
CREO
Creo Medical
0.5$224.00+1.3%£353.68 million£8,154.00-18.06
Synairgen logo
SNG
Synairgen
0.4$171.92+1.1%£339.85 million£79,000.00-33.71Gap Down
SPEC
Inspecs Group plc (SPEC.L)
1.3$326.00+0.3%£329.63 million£47.58 million-18.74
EKF Diagnostics Holdings plc (EKF.L) logo
EKF
EKF Diagnostics Holdings plc (EKF.L)
0.8$71.00+4.2%£309.40 million£49.81 million50.71Gap Down
Tristel plc (TSTL.L) logo
TSTL
Tristel plc (TSTL.L)
0.6$595.50+0.8%£279.97 million£33.80 million53.17Insider Selling
News Coverage
ARIX
Arix Bioscience
1.0$191.16+1.0%£261.82 million£23.47 million13.65Upcoming Earnings
ECO Animal Health Group logo
EAH
ECO Animal Health Group
1.1$345.00+1.6%£229.33 million£86.32 million69.00
Bioventix logo
BVXP
Bioventix
0.9$4,300.00+1.5%£220.60 million£10.31 million31.18
Tiziana Life Sciences PLC (TILS.L) logo
TILS
Tiziana Life Sciences PLC (TILS.L)
0.7$109.90+4.5%£204.34 millionN/A-19.98
ORPH
Open Orphan
0.0$29.74+0.8%£197.08 million£10.57 million-9.30
ANGLE logo
AGL
ANGLE
0.4$83.40+0.5%£180.55 million£722,500.00-16.04
Redx Pharma Plc (REDX.L) logo
REDX
Redx Pharma Plc (REDX.L)
0.9$66.00+0.0%£178.03 million£5.69 million-12.22News Coverage
Scancell Holdings plc (SCLP.L) logo
SCLP
Scancell Holdings plc (SCLP.L)
0.6$21.35+0.2%£173.64 millionN/A-15.25
DDDD
4D pharma
0.6$128.11+0.7%£169.63 million£486,000.00-4.05News Coverage
Gap Down
Omega Diagnostics Group PLC (ODX.L) logo
ODX
Omega Diagnostics Group PLC (ODX.L)
0.3$92.20+2.4%£162.02 million£8.52 million-20.95Gap Down
Faron Pharmaceuticals Oy (FARN.L) logo
FARN
Faron Pharmaceuticals Oy (FARN.L)
0.6$327.50+0.0%£153.59 millionN/A-2.99
MGP
Medica Group
1.1$137.93+0.1%£153.57 million£41.55 million31.35
Advanced Oncotherapy logo
AVO
Advanced Oncotherapy
0.4$41.50+2.4%£139.84 millionN/A-4.23
Mereo BioPharma Group plc (MPH.L) logo
MPH
Mereo BioPharma Group plc (MPH.L)
0.6$26.50+1.9%£138.87 millionN/A-0.21Gap Up
This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.